πŸ‡ΊπŸ‡Έ FDA
Patent

US 9885047

Modulation of TMPRSS6 expression

granted A61KA61K31/713A61K45/06

Quick answer

US patent 9885047 (Modulation of TMPRSS6 expression) held by Ionis Pharmaceuticals, Inc. expires Mon Feb 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ionis Pharmaceuticals, Inc.
Grant date
Tue Feb 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
33
CPC classes
A61K, A61K31/713, A61K45/06